<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292756</url>
  </required_header>
  <id_info>
    <org_study_id>0118U001612/4</org_study_id>
    <nct_id>NCT04292756</nct_id>
  </id_info>
  <brief_title>Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment</brief_title>
  <acronym>COAST_UA_AMD</acronym>
  <official_title>Safety and Effectiveness of Triamcinolone Acetonide in Patients With Serous Pigment Detachment Associated With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Filatov Institute of Eye Diseases and Tissue Therapy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odessa National Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mykolaiv Region Ophthalmogical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Polyclinic of Internal Affairs of Ukraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Filatov Institute of Eye Diseases and Tissue Therapy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of triamcinolone&#xD;
      acetonide in patients with serous pigment detachment associated with age-related macular&#xD;
      degeneration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of triamcinolone&#xD;
      acetonide in patients with serous pigment epithelial detachment associated with age-related&#xD;
      macular degeneration.&#xD;
&#xD;
      This study is planned as a follow-up. Patients with with serous pigment epithelial detachment&#xD;
      associated with age-related macular degeneration included in it will receive triamcinolone&#xD;
      acetonide in accordance with the approved indications for use indicated in the instructions&#xD;
      for the use of drugs in Ukraine.&#xD;
&#xD;
      The treatment proposed in this study is based on the world experience and scientific&#xD;
      developments of the Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of&#xD;
      Ukraine &quot;. Therefore, it is expected that the benefit / risk ratio in relation to the&#xD;
      participation in this study should not be different from that described in the scientific&#xD;
      literature and the benefits outweigh the risk. It is known that the absence of treatment in&#xD;
      these diseases leads to an irreparable loss of central vision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Chart</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>Defined study baseline range of ETDRS equivalent of 20/200 to 20/20) in the study eye; a higher score represents better functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Flattened Pigment Epithelial Detachment</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>Number of flattened pigment epithelial detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>A negative number indicates improvement (reduced thickness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Injections</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>The number of injections administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>The difference between intraocular pressure at baseline and at Month 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subtenon injection of 40 mg triamcinolone acetonide</intervention_name>
    <description>Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.</description>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection of 4 mg triamcinolone acetonide</intervention_name>
    <description>Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visometry</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fluorescent angiography</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Refractometry</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Slit lamp examination</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ophthalmoscopy</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OKT</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IOP</intervention_name>
    <description>Ophthalmic examination</description>
    <arm_group_label>Triamcinolone Acetonide 4 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read (or, if unable to read due to visual impairment, be read to verbatim by&#xD;
             the person administering the informed consent form or a family member) and understand&#xD;
             the informed consent form and willing to sign the informed consent form.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Men and women ≥ 50 years of age.&#xD;
&#xD;
          -  Willing, committed, and able to return for all clinic visits and complete all&#xD;
             study-related procedures.&#xD;
&#xD;
          -  Naive serous pigment epithelial detachment associated with AMD as defined on FA and&#xD;
             OCT.&#xD;
&#xD;
          -  Transparent optical media and possibility to mydriasis.&#xD;
&#xD;
          -  Best corrected visual acuity at least 20/100 Equivalent of Snellen (ETDRS).&#xD;
&#xD;
          -  Absence of signs of CNV, angiomatous retina proliferation, polypoid choriovasculopathy&#xD;
             defined on FA and OCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular media of insufficient quality to obtain fundus and OCT images in the study eye.&#xD;
&#xD;
          -  Previous intravitreal injections of anti-VEGF drugs in the study eye.&#xD;
&#xD;
          -  Any injections of corticosteroids (intravitreal, subtenon, subconjunctival or&#xD;
             parabulbar) or implantation of medical device in the study eye.&#xD;
&#xD;
          -  Ocular inflammation or external ocular inflammation in the study eye.&#xD;
&#xD;
          -  Concurrent disease in the study eye that would compromise BCVA or require medical or&#xD;
             surgical intervention during the study period.&#xD;
&#xD;
          -  Any ocular disorder in the study eye that, in the opinion of the investigator, may&#xD;
             confound interpretation of the study results.&#xD;
&#xD;
          -  Significant scarring or atrophy in the fovea that indicates substantial irreversible&#xD;
             vision loss in the study eye.&#xD;
&#xD;
          -  Evidence at examination of infectious blepharitis, keratitis, scleritis, or&#xD;
             conjunctivitis in either eye or current treatment for serious systemic infection.&#xD;
&#xD;
          -  Vitreomacular traction or traction retinal detachment, epiretinal membrane in study&#xD;
             eye.&#xD;
&#xD;
          -  Any iris neovascularization and/or vitreous hemorrhage in either eye.&#xD;
&#xD;
          -  Uncontrolled glaucoma, or previous filtration surgery in either eye.&#xD;
&#xD;
          -  Maсular hole.&#xD;
&#xD;
          -  Any prior treatment with photodynamic therapy in the study eye.&#xD;
&#xD;
          -  Cataract surgery within 3 months prior to Day 1 in the study eye.&#xD;
&#xD;
          -  Yttrium-aluminum-garnet laser capsulotomy within 2 months prior to Day 1 in the study&#xD;
             eye.&#xD;
&#xD;
          -  Any other intraocular surgery within 3 months prior to Day 1 in the study eye.&#xD;
&#xD;
          -  History of vitreoretinal surgery and/or scleral buckle surgery in the study eye.&#xD;
&#xD;
          -  Previous assignment to treatment during this study.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  History of cerebrovascular disease or myocardial infarction within 6 months prior to&#xD;
             Baseline/Day 1.&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug, may affect interpretation of the&#xD;
             results of the study, or renders the subject at high risk from treatment&#xD;
             complications.&#xD;
&#xD;
          -  Women of childbearing potential without contraception, women who intend to breastfeed&#xD;
             during the study. All subjects (both men and women) of childbearing potential who are&#xD;
             unwilling to use adequate birth control measures during the course of the study.&#xD;
&#xD;
          -  Renal failure requiring dialysis or renal transplant.&#xD;
&#xD;
          -  Participation in an investigational study within 30 days prior to Screening/Visit 1&#xD;
             that involved treatment with any drug (excluding vitamins and minerals) or device.&#xD;
&#xD;
          -  Known serious allergy to the fluorescein sodium for injection in angiography or&#xD;
             Verteporfin.&#xD;
&#xD;
          -  Inability to obtain fundus photographs or fluorescein angiograms of sufficient&#xD;
             quality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrii MD Korol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Filatov Institute of Eye Diseases and Tissue Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrii MD Korol, PhD</last_name>
    <phone>+380936327266</phone>
    <email>andrii.r.korol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viktoriia MD Rostel</last_name>
    <phone>+380976126589</phone>
    <email>rostelviktoria@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odessa National Medical University</name>
      <address>
        <city>Odessa</city>
        <state>Please Select</state>
        <zip>65061</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadiia Ulianova, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CPUkraine</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Parhomenko, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mykolaiv Region Ophthalmogical Hospital</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krasymira Rylkovа, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Filatov Institute of Eye Diseases and Tissue Therapy</name>
      <address>
        <city>Odessa</city>
        <zip>65061</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>V Pasyechnikova N, A Naumenko V, R Korol A, S Zadorozhnyy O, B Kustrin T, O Nasinnyk I. Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach. Med Hypothesis Discov Innov Ophthalmol. 2012 Winter;1(4):72-5.</citation>
    <PMID>24600628</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Filatov Institute of Eye Diseases and Tissue Therapy</investigator_affiliation>
    <investigator_full_name>Andrii Korol, MD, PhD</investigator_full_name>
    <investigator_title>Head of Laser Department</investigator_title>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>serous pigment epithelium detachment</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

